Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
2 clusters · 3 sources · 16 days · First seen · Last updated
Pimicotinib development for TGCT
Overview
Clinical data from the phase 3 MANEUVER trial indicated that pimicotinib provides durable responses and sustained improvements for patients with tenosynovial giant cell tumor (TGCT). Findings presented at the ESMO Congress 2026 showed that the objective response rate remained stable, with tumor volume scores increasing from 74.6% at one year to 77.8% at two years. Patients also experienced improvements in joint mobility, pain, and stiffness.
Following these results, the U.S. Food and Drug Administration approved pimicotinib (PIMJETMI) for the systemic treatment of adults with symptomatic TGCT, particularly for those where surgical resection might cause severe morbidity. The drug is a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor. The FDA label includes warnings regarding hepatotoxicity, embryo-fetal toxicity, and increases in serum creatinine.
Entities
Leiden University Medical Center · PIMJETMI · Merck · MANEUVER trial · Pimicotinib
Timeline
-
[HEALTH] 3 sourcesFDA approves pimicotinib for tenosynovial giant cell tumor
The FDA has approved PIMJETMI (pimicotinib) as a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT).
-
[HEALTH] 2 sourcesPimicotinib shows sustained benefits in TGCT phase 3 trial
Two-year MANEUVER trial data show pimicotinib provides durable tumor responses and sustained improvements in pain, stiffness, and joint mobility for TGCT patients.
Sources
checkrare.com · novumpr.nl · oncnursingnews.com